Drugs / ONCOS-102
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03003676 | Dec 2016 → Jul 2020 | — | Targovax Oy | Completed | No outcome recorded |
| Phase 1 | NCT01598129 | Apr 2012 → Oct 2013 | cancer | Targovax Oy | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03514836 | May 2018 → Jan 2021 | castration-resistant prostate carcinoma | SOTIO a.s. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02963831 | Sep 2017 → Jun 2022 | appendix cancer, ovarian carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02879669 | Jun 2016 → May 2020 | — | Targovax Oy | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05561491 | Jan 2024 → Jun 2027 | cutaneous melanoma | Targovax Oy | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONCOS-102 | “ONCOS-102 administration will start within 3 weeks of leukapheresis at Week 5 (35 days since baseline +/- 2 days), and 3 further doses will be administered on a weekly basis” NCT03514836 ↗ |
| Known as | CGTG-102 | “ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers” NCT01598129 ↗ |
| Route | Intravenous | “for intratumoral and intravenous injection” NCT01598129 ↗ |